Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine cancer types. METHODS: A phase 1 clinical trial was...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Vonderheide, Robert H, Kraynyak, Kimberly A, Shields, Anthony F, McRee, Autumn J, Johnson, Jennifer M, Sun, Weijing, Chintakuntlawar, Ashish V, Pawlicki, Jan, Sylvester, Albert J, McMullan, Trevor, Samuels, Robert, Kim, Joseph J, Weiner, David, Boyer, Jean D, Morrow, Matthew P, Humeau, Laurent, Skolnik, Jeffrey M
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2021
Soggetti:
Clinical/Translational Cancer Immunotherapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8261871/
https://ncbi.nlm.nih.gov/pubmed/34230114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-003019
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi